Physician

Shadan Mansoor, M.D.

According to 2025 Medicare claims, Shadan Mansoor, M.D. (NPI: 1679523088) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Johnson, TX. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY CONSULTANTS PA (NPI: 1629021159; TIN: 752512142) and primary practice location at 76028-7220. Mansoor is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Mansoor's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 413 traditional Medicare patients, billed 153,664 HCPCS/CPT codes, and received $2,807,522 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,009 prescription claims across 244 beneficiaries totaling $2,175,181 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 40 claims. Open Payments data shows 24 records totaling $688. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $780,157 to $2,175,181. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	573	216,271	$1,961,433
2016	583	227,557	$2,086,971
2017	585	202,020	$2,279,238
2018	603	203,530	$2,259,442
2019	530	193,726	$2,848,854
2020	509	195,324	$2,833,211
2021	498	192,556	$2,770,602
2022	521	182,413	$2,507,943
2023	448	222,330	$2,995,298
2024	413	153,664	$2,807,522

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	157	797	$780,157
2016	173	998	$691,950
2017	208	1,023	$979,263
2018	229	1,040	$1,486,349
2019	249	1,329	$1,872,485
2020	241	1,504	$2,174,735
2021	257	1,482	$2,745,226
2022	239	1,248	$3,002,851
2023	246	1,100	$2,651,910
2024	244	1,009	$2,175,181

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	132	$25,657
2016	N/R	69	$28,916
2017	N/R	42	$12,983
2018	N/R	N/R	N/R
2019	N/R	25	$2,698
2020	N/R	35	$2,878
2021	N/R	55	$4,220
2022	N/R	32	$1,119
2023	N/R	40	$3,742
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	82	396	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	254	554	$92
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	78	230	$92
71260	Ct scan of chest with contrast	63	105	$47
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	163	250	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	24	672	$368,868
Pomalyst	Pomalidomide	13	364	$272,378
Lenalidomide	Lenalidomide	13	294	$142,362
Verzenio	Abemaciclib	11	308	$131,697
Imatinib Mesylate	Imatinib Mesylate	36	1,080	$82,484

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$688	Blueprint Medicines Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shadan Mansoor, M.D.?

Tedicare shows public-source Medicare data for Shadan Mansoor, M.D. (NPI 1679523088), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shadan Mansoor, M.D. have ACO affiliation data?

Shadan Mansoor, M.D. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Shadan Mansoor, M.D.?

Shadan Mansoor, M.D. is linked to ONCOLOGY-HEMATOLOGY CONSULTANTS PA (billing NPI 1629021159) in the available physician profile data.

Does Shadan Mansoor, M.D. have Open Payments data?

Shadan Mansoor, M.D. has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.